CDC 501 en es it fr

CDC 501 Brand names, CDC 501 Analogs

CDC 501 Brand Names Mixture

  • No information avaliable

CDC 501 Chemical_Formula


CDC 501 RX_link

CDC 501 fda sheet


CDC 501 msds (material safety sheet)

CDC 501 Synthesis Reference

No information avaliable

CDC 501 Molecular Weight

252.268 g/mol

CDC 501 Melting Point

215.5 oC

CDC 501 H2O Solubility

308 mg/L at 25 oC (SRC PhysProp estimated -- MEYLAN,WM et al. (1996))

CDC 501 State


CDC 501 LogP


CDC 501 Dosage Forms

Suspension; Tablet (150 mg, 300 mg and 600 mg film coated)

CDC 501 Indication

For use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults with epilepsy and as adjunctive therapy in the treatment of partial seizures in children ages 4-16 with epilepsy.

CDC 501 Pharmacology

Oxcarbazepine is structurally a derivative of carbamazepine, adding an extra oxygen atom to the benzylcarboxamide group. This difference helps reduce the impact on the liver of metabolizing the drug, and also prevents the serious forms of anemia occasionally associated with carbamazepine. Aside from this reduction in side effects, it is thought to have the same mechanism as carbamazepine - sodium channel inhibition - and is generally used to treat the same conditions.

CDC 501 Absorption

Completely absorbed following oral administration. Food has no effect on the rate and extent of absorption of oxcarbazepine.

CDC 501 side effects and Toxicity

Isolated cases of overdose with oxcarbazepine have been reported. The maximum dose taken was approximately 24,000 mg. All patients recovered with symptomatic treatment.

CDC 501 Patient Information

CDC 501 Organisms Affected

Humans and other mammals